We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Safety monitoring and information (121)
- Compliance and enforcement (32)
- Import and export (28)
- Shortages and supply disruptions (17)
- Sunscreens (7)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
572 result(s) found, displaying 526 to 550
-
Safety alertsWe are investigating adverse reactions to the 2010 flu vaccine in young children in Western Australia and have paused its use for kids under 5.
-
-
Safety alertsConsumers are advised to stop using Hydroxycut products due to reports of serious adverse reactions, including liver toxicity, and to consult their doctor if they have any concerns.
-
Safety alertsBe aware that Hydroxycut products purchased via the internet may be sourced from the US and may contain ingredients which are not permitted in low-risk medicines in Australia
-
Safety alertsWeight loss drug Sibutramine (Reductil) under safety review for cardiovascular risks.
-
Safety alertsWe are advising that there are supply issues with Physeptone (methadone) tablets due to quality control problems.
-
Safety alertsApproval has been granted for the Panvax H1N1 vaccine in children starting at 6 months, with Panvax H1N1 Junior for ages 6 months to 3 years.
-
Safety alerts
-
-
Safety alertsGinkgo biloba products with high quercetin and rutin levels have been identified. Quality standards are being reviewed.
-
Safety alertsPanvax H1N1 influenza vaccine has been approved for use in adults and children over 10 years old, with additional data needed for younger children.
-
Safety alertsAdvise to exercise caution when using Australian Hydroxycut products
-
Market actionsChuan Xiong Cha Tiao Wan pills have been recalled due to the presence of aristolochic acids, which can cause severe kidney damage and urinary tract cancer. Stop using them immediately and consult your doctor for advice.
-
Market actions
-
Market actions
-
Safety alerts
-
Market actionsClexane (enoxaparin) is being recalled due to contamination concerns, and patients should check with their doctor or pharmacist to see if their supply is affected.
-
Market actionsConsumers should stop using Clexane (enoxaparin) from the newly recalled batch due to impurity concerns. Check with your doctor or pharmacist to see if your supply is affected and return any contaminated product. If you have any concerns, consult your doctor.
-
-
Market actionsCertain batches of Clexane (enoxaparin) have been recalled because of an impurity. Stop using it, check with your healthcare provider, and return any affected product. If you have concerns, consult your doctor.
-
Safety alerts
-
Market actionsContinuing Australian reporting of bizarre and sometimes dangerous sleep related behaviours such as sleep walking and sleep driving in some users of zolpidem.
-
Market actions
-
Safety alertsPhenylpropanolamine is no longer available in Australia due to safety concerns, including the risk of haemorrhagic stroke. Consult your doctor if you have concerns.
-
Safety alertsParoxetine use in early pregnancy may increase the risk of congenital malformations, particularly heart defects, so women planning to become pregnant or in early pregnancy should consult their doctor.